Literature DB >> 10225838

Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients.

D J Witt1, C C Ginocchio, X P Wang, M K Kaufman.   

Abstract

Together with CD4(+)-cell counts as an indicator of immune function, the use of human immunodeficiency virus type 1 (HIV-1) RNA levels as a direct marker of viral load has gained widespread attention for evaluation of patient clinical status. Results obtained with other HIV-1 markers for this purpose are often inconsistent. This study examined the relationship between various HIV-1 markers by using clinical specimens (plasma) from HIV-1-infected individuals at different stages of disease progression and supernatant fluid from four human T-lymphocyte cell lines chronically infected with HIV-1. Cell culture specimens were collected periodically over 7 days and were tested for HIV-1 RNA levels with a nucleic acid amplification assay, for p24 with an enzyme-linked immunosorbent assay, and for reverse transcriptase activity by isotope uptake. An increase in the level of each marker was observed over the 7-day period with each of the four HIV-1 strains tested (LAV1, HTLV-IIIB, MN, and ARV2); with these specimens, the frequency of detection for each marker was 100%. In the clinical specimens, HIV-1 RNA was detected more often (143 of 183 specimens [78%]) than was p24 (87 of 183 [48%]); little correlation between the levels of the two markers was seen. In these clinical specimens evaluated, CD4(+)-cell counts were better correlated with the frequency and levels of HIV-1 RNA than with p24. In specimens (n = 38) collected serially from six HIV-1-infected subjects, HIV-1 RNA was detected more often (33 of 38 [85%]) than p24 (23 of 38 [59%]). When reported by the assays used, the levels of both HIV-1 markers fluctuated over time for each of the subjects. Although the markers correlated in the in vitro systems studied, the observed differences in the correlation of levels and frequencies of HIV-1 markers in vivo indicate that p24 has less clinical utility than does viral load testing when used in conjunction with CD4(+)-cell counts as a measure of immune system functioning.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225838      PMCID: PMC103725          DOI: 10.1128/CDLI.6.3.369-376.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  26 in total

1.  Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons.

Authors:  R M Donovan; C E Bush; N P Markowitz; D M Baxa; L D Saravolatz
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 2.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

3.  Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

Authors:  A M Vandamme; J C Schmit; S Van Dooren; K Van Laethem; E Gobbers; W Kok; P Goubau; M Witvrouw; W Peetermans; E De Clercq; J Desmyter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

4.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

5.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; E S Daar; M S Simberkoff; J D Hamilton
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

Review 7.  Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.

Authors:  R T Schooley
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

8.  Detection of low HIV-1 RNA levels in plasma.

Authors:  G A Schockmel; S Yerly; L Perrin
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

9.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.